Develops drugs for hereditary angioedema and amyloidosis.
Jun 2026Revenue $59.5M/yrExpenses $483M/yr
No trendCash runway ≈ 1.3 years from Jun 2026
Figures by year
When will Intellia Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $59.5M and expenses $483M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $67.7M | $509M | −$441M |
| Dec 2024 | $57.9M | $592M | −$534M |
| Dec 2023 | $36.3M | $552M | −$515M |
| Dec 2022 | $52.1M | $510M | −$458M |
| Dec 2021 | $33.1M | $301M | −$268M |
| Dec 2020 | $58.0M | $195M | −$137M |
| Dec 2019 | $43.1M | $149M | −$106M |
| Dec 2018 | $30.4M | $121M | −$90.9M |
| Dec 2017 | $26.1M | $95.7M | −$69.6M |
| Dec 2016 | $16.5M | $48.6M | −$32.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.